Patents by Inventor Kyle HAVENS

Kyle HAVENS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PCSK9 endonuclease variants, compositions, and methods of use
    Patent number: 11779654
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PCSK9 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of hypercholesterolemia or a condition associated therewith.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: October 10, 2023
    Assignee: 2SEVENTY BIO, INC.
    Inventors: Jordan Jarjour, Kyle Havens, Michael Certo, Max Echterling
  • CBLB endonuclease variants, compositions, and methods of use
    Patent number: 11732255
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: August 22, 2023
    Assignee: 2seventy bio, Inc.
    Inventors: Jordan Jarjour, Kyle Havens, Anne-Rachel Krostag
  • TGFBetaR2 endonuclease variants, compositions, and methods of use
    Patent number: 11530395
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a TGF?R2 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: December 20, 2022
    Assignee: 2seventy bio, Inc.
    Inventors: Jordan Jarjour, Kyle Havens
  • PDCD-1 HOMING ENDONUCLEASE VARIANTS
    Publication number: 20220177860
    Abstract: The present disclosure provides improved homing endonuclease variants and megaTALs reprogrammed to bind and cleave the PDCD-1 gene.
    Type: Application
    Filed: December 9, 2019
    Publication date: June 9, 2022
    Applicant: 2Seventy bio, Inc.
    Inventors: JORDAN JARJOUR, KYLE HAVENS, JASDEEP MANN
  • HOMING ENDONUCLEASE VARIANTS
    Publication number: 20220119784
    Abstract: The present disclosure provides homing endonuclease variants and megaTALs reprogrammed to bind and cleave a polynucleotide sequence in the genome. The homing endonuclease variants and megaTALs have been engineered to increase the thermostability and/or activity.
    Type: Application
    Filed: December 9, 2019
    Publication date: April 21, 2022
    Applicant: 2seventy bio, Inc.
    Inventors: JORDAN JARJOUR, KYLE HAVENS, CONSTANTINE CHRYSOSTOMOU
  • CBLB ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20210214714
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Application
    Filed: January 15, 2021
    Publication date: July 15, 2021
    Applicant: bluebird bio, Inc.
    Inventors: Jordan JARJOUR, Kyle HAVENS, Anne-Rachel KROSTAG
  • CBLB ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20210214700
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Application
    Filed: January 15, 2021
    Publication date: July 15, 2021
    Applicant: bluebird bio, Inc.
    Inventors: Jordan JARJOUR, Kyle HAVENS, Anne-Rachel KROSTAG
  • CBLB ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20210147818
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Application
    Filed: May 25, 2018
    Publication date: May 20, 2021
    Applicant: bluebird bio, Inc.
    Inventors: Jordan JARJOUR, Kyle HAVENS, Anne-Rachel KROSTAG
  • CBLB endonuclease variants, compositions, and methods of use
    Patent number: 10927367
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: February 23, 2021
    Assignee: bluebird bio, Inc.
    Inventors: Jordan Jarjour, Kyle Havens, Anne-Rachel Krostag
  • CTLA4 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20210002621
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a CTLA4 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Application
    Filed: December 20, 2018
    Publication date: January 7, 2021
    Applicant: bluebird bio, Inc.
    Inventors: JORDAN JARJOUR, KYLE HAVENS
  • PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20200376140
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PCSK9 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of hypercholesterolemia or a condition associated therewith.
    Type: Application
    Filed: October 4, 2018
    Publication date: December 3, 2020
    Applicant: bluebird bio, Inc.
    Inventors: JORDAN JARJOUR, KYLE HAVENS, MICHAEL CERTO, MAX ECHTERLING
  • CBLB endonuclease variants, compositions, and methods of use
    Patent number: 10793843
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: October 6, 2020
    Assignee: bluebird bio, Inc.
    Inventors: Jordan Jarjour, Kyle Havens, Anne-Rachel Krostag
  • TGFBetaR2 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20200123515
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a TGF?R2 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Application
    Filed: October 17, 2017
    Publication date: April 23, 2020
    Applicant: bluebird bio, Inc.
    Inventors: Jordan JARJOUR, Kyle HAVENS
  • CBLB ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20200109385
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Application
    Filed: November 25, 2019
    Publication date: April 9, 2020
    Applicant: bluebird bio, Inc.
    Inventors: Jordan JARJOUR, Kyle HAVENS, Anne-Rachel KROSTAG
  • CBLB ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20200087653
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Application
    Filed: November 25, 2019
    Publication date: March 19, 2020
    Applicant: bluebird bio, Inc.
    Inventors: Jordan JARJOUR, Kyle HAVENS, Anne-Rachel KROSTAG
  • IL-10 RECEPTOR ALPHA HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20190309274
    Abstract: The invention provides improved genome editing compositions and methods for editing an IL-10R? gene. The invention further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, GVHD, a transplant rejection, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Application
    Filed: August 15, 2017
    Publication date: October 10, 2019
    Applicant: bluebird bio, Inc.
    Inventors: Kyle HAVENS, Jordan JARJOUR
  • TIM3 HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20190262398
    Abstract: The invention provides improved genome editing compositions and methods for editing a TIM3 gene. The invention further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
    Type: Application
    Filed: August 23, 2017
    Publication date: August 29, 2019
    Applicant: bluebird bio, Inc.
    Inventors: Kyle HAVENS, Jordan JARJOUR